On February 16, Unicamp received a visit from directors from Xamano Biotech, a leading Chinese company in the distribution of vaccines, medicines, equipment and health products. The pharmaceutical company presented its projects and technologies under development and expressed its intention to establish research and technology transfer partnerships.
"The Xamano Group has a policy of assisting in the construction of knowledge and the transfer of technologies. This shows the company's sense of social responsibility", explained Professor Li Li Min, professor at the Faculty of Medical Sciences (FCM) and leader of the Group of Innovation and Health Management (GIGS). The meeting was attended by the rector of Unicamp, professor Antonio José de Almeida Meirelles; the general coordinator of the University, professor Maria Luiza Moretti; the Dean of Research, Professor João Marcos Romano; by Professor Li Li Min; members of the Executive Board of International Relations (Deri); from the Unicamp Innovation Agency (Inova) and members of the Unicamp Task Force against Covid-19.
Among the innovations developed by the group are vaccines and drugs for infectious and oncological diseases. "The company has a large portfolio of products, both medicines and medical equipment. There is a project developing treatments for Covid-19, which is the biggest challenge at the moment", highlights Li. According to the professor, the pharmaceutical company has of medicines in the clinical testing phase that can be developed at Unicamp.
Another possibility discussed at the meeting is the mobility of teachers and researchers between the two countries. In March, Xamano will bring to Brazil Yan-Liu, professor at Fudan University, in Shanghai, and member of the Chinese committee to combat Covid-19. Unicamp is included among the institutions that will be visited. "It is important for the University to get to know China better, we have little knowledge about the country's scientific production. This opens up a good perspective for international collaboration with Chinese universities", analyzes Li Li Min.
Read more:
Meeting at FCM with pharmaceutical giant discusses new investments in research
